Home/ Stocks/ CNTX

Context Therapeutics Inc. Common Stock

CNTX XNAS

$3.18 +0.21 (+6.95%) ▲ 15-min delayed

Open

$3.28

High

$3.30

Low

$3.05

Volume

681.2K

Market Cap

$277.48M

About Context Therapeutics Inc. Common Stock

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 9 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	N/A	$-9,693,237	$-0.10
Q2 2025	N/A	$-8,827,510	$-0.09
Q1 2025	N/A	$-4,577,261	$-0.05
FY 2024	N/A	$-26,725,104	$-0.46

Related Market News

No specific coverage for CNTX yet. Check out our latest market news or earnings calendar.

Get CNTX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Context Therapeutics Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.